Neumora Therapeutics, Inc. (NMRA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Neumora Therapeutics, Inc. (NMRA) closed at USD 0.35 on 2026-10-14, a change of -86.3 % over the past year, with a market capitalization of USD 80.23M.

Neumora Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Neumora Therapeutics, Inc. key figures

Previous close

USD 0.35 (2026-10-14)

1-year change

-86.3 %

Market cap

USD 80.23M

Enterprise value

USD 16.65M

P/E ratio (trailing)

-0.35

P/E ratio (forward)

-0.64

EPS (trailing)

-1.23

EPS (forward)

-0.67

PEG ratio

n/a

Price to book

1.79

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.06

Employees

63

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Neumora Therapeutics, Inc. and compare it with other stocks.